{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T22:21:14Z","timestamp":1783635674271,"version":"3.55.0"},"reference-count":15,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Derm Venereol"],"DOI":"10.2340\/actadv.v105.44310","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:47:15Z","timestamp":1761223635000},"page":"adv44310","source":"Crossref","is-referenced-by-count":4,"title":["The Absence of Recent Systemic Therapy can be a Significant Risk Factor for Nemolizumab-associated Cutaneous Adverse Events in Patients with Prurigo Nodularis: A Single-centre Retrospective Study"],"prefix":"10.2340","volume":"105","author":[{"given":"Yoshihito","family":"Mima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masako","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Iozumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1183","published-online":{"date-parts":[[2025,10,23]]},"reference":[{"key":"130652","doi-asserted-by":"crossref","unstructured":"Pereira MP, Steinke, S, Zeidler C, Forner C, Riepe C, Augustin M, et al. European Academy of Dermatology and Venereology European prurigo project: expert consensus on the definition, classification and terminology of chronic prurigo. J Eur Acad Dermatol Venereol 2018; 32: 1059\u20131065.","DOI":"10.1111\/jdv.14570"},{"key":"130653","doi-asserted-by":"crossref","unstructured":"Kwatra SG, St\u00e4nder S, Yosipovitch G, Kim BS, Levit NA, O\u2019Malley JT. Pathophysiology of prurigo nodularis: neuroimmune dysregulation and the role of Type 2 inflammation. J Invest Dermatol 2025; 145: 249\u2013256.","DOI":"10.1016\/j.jid.2024.06.1276"},{"key":"130654","doi-asserted-by":"crossref","unstructured":"Yosipovitch G, Mollanazar N, St\u00e4nder S, Kwatra SG, Kim BS, Laws E, et al. Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials. Nat Med 2023; 29: 1180\u20131190.","DOI":"10.1038\/s41591-023-02320-9"},{"key":"130655","doi-asserted-by":"crossref","unstructured":"Kwatra SG, Yosipovitch G, Legat FJ, Reich A, Paul C, Simon D, et al. Phase 3 trial of nemolizumab in patients with prurigo nodularis. N Engl J Med 2023; 389: 1579\u20131589.","DOI":"10.1056\/NEJMoa2301333"},{"key":"130656","unstructured":"US Food and Drug Administration. Novel drug approvals for 2024. Available from: https:\/\/www.fda.gov\/drugs\/novel-drug-approvals-fda\/novel-drug-approvals-2024"},{"key":"130657","doi-asserted-by":"crossref","unstructured":"Mima Y, Yamamoto M, Iozumi K. Cutaneous adverse events following nemolizumab administration: a review. J Clin Med 2025; 14: 3026.","DOI":"10.3390\/jcm14093026"},{"key":"130658","doi-asserted-by":"crossref","unstructured":"Mima Y, Yamamoto M, Iozumi K. Transient elevation of eosinophil and thymus and activation-regulated chemokine levels associated with cutaneous adverse events due to nemolizumab: a case report. Dermatitis 2025 Sep 12. [Online ahead of print].","DOI":"10.1177\/17103568251380242"},{"key":"130659","doi-asserted-by":"crossref","unstructured":"Mima Y, Ohtsuka T. A Case of erythema multiforme following the administration of nemolizumab. Cureus 2025; 17: e79070.","DOI":"10.7759\/cureus.79070"},{"key":"130660","doi-asserted-by":"crossref","unstructured":"Mima Y, Yamamoto M, Iozumi K. Four cases of prurigo nodularis requiring nemolizumab due to persistent pruritus or lesions after dupilumab treatment. Acta Derm Venereol 2025; 105: adv43419.","DOI":"10.2340\/actadv.v105.43419"},{"key":"130661","doi-asserted-by":"crossref","unstructured":"Mima Y, Yamamoto M, Iozumi K. Effectiveness of nemolizumab in improving dialysis-associated pruritus refractory to difelikefalin: a case report. Cureus 2025; 17: e83367.","DOI":"10.7759\/cureus.83367"},{"key":"130662","doi-asserted-by":"crossref","unstructured":"Sasaki W, Saito R, Suzuki K, Watanabe D, Minami-Hori M, Kamada H, et al. Clinical characteristics and risk factors for cutaneous manifestations associated with nemolizumab in atopic dermatitis: a multicenter retrospective study in Japan. J Dermatol 2025 Jul 23. [Online ahead of print].","DOI":"10.1111\/1346-8138.17877"},{"key":"130663","doi-asserted-by":"crossref","unstructured":"Dillon SR, Sprecher C, Hammond A, Bilsborough J, Rosenfeld-Franklin M, Presnell SR, et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol 2004; 5: 752\u2013760.","DOI":"10.1038\/ni1084"},{"key":"130664","doi-asserted-by":"crossref","unstructured":"Bilsborough J, Mudri S, Chadwick E, Harder B, Dillon SR. IL-31 receptor (IL-31RA) knockout mice exhibit elevated responsiveness to oncostatin M. J Immunol 2010; 185: 6023\u20136030.","DOI":"10.4049\/jimmunol.0902769"},{"key":"130665","doi-asserted-by":"crossref","unstructured":"Kabashima K, Matsumura T, Komazaki H, Kawashima M. Trial of nemolizumab and topical agents for atopic dermatitis with pruritus. N Engl J Med 2020; 383: 141\u2013150.","DOI":"10.1056\/NEJMoa1917006"},{"key":"130666","doi-asserted-by":"crossref","unstructured":"Sekiya T, Tsunemi Y, Miyamasu M, Ohta K, Morita A, Saeki H, et al. Variations in the human Th2-specific chemokine TARC gene. Immunogenetics 2003; 54: 742\u2013745.","DOI":"10.1007\/s00251-002-0520-2"}],"container-title":["Acta Dermato-Venereologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/44310\/51809","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/44310\/51809","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:47:21Z","timestamp":1761223641000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/view\/44310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":15,"URL":"https:\/\/doi.org\/10.2340\/actadv.v105.44310","relation":{},"ISSN":["1651-2057","0001-5555"],"issn-type":[{"value":"1651-2057","type":"electronic"},{"value":"0001-5555","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,23]]}}}